VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer to Drive Growth in Liver and Gastrointestinal In-Vitro Models and Toxicology Services Market.

VivoSim Labs has appointed Tony Lialin as Chief Commercial Officer, bringing over two decades of experience in turning life science platforms into scalable revenue. Lialin will lead go-to-market strategy, partnerships, and expansion of the company's San Diego-based services that combine organ-specific 3D models with AI-driven analytics. The global liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024, with the United States accounting for $325M. Adoption of 3D human-relevant systems is rising, with a 5.9% CAGR from 2020 to 2024.

VivoSim Labs, Inc. has appointed Tony Lialin as its Chief Commercial Officer, leveraging his over two decades of experience in transforming life science platforms into scalable revenue streams. Lialin will lead the company's go-to-market strategy, partnerships, and the expansion of its San Diego-based services that combine organ-specific 3D models with AI-driven analytics [1][2].

The appointment comes at a time when the global liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024, with the United States accounting for $325M [3]. The adoption of 3D human-relevant systems is rising, with the global in vitro liver model market growing at a 5.9% CAGR from 2020 to 2024 [2].

Tony Lialin brings a proven track record of building commercial teams from the ground up and forging strategic pharma partnerships. He has successfully scaled multiple businesses, including closing Illumina’s largest-ever deal ($157M PO) and managing a $403M quota across GRAIL, Natera, and AncestryDNA [1]. At VivoSim Labs, he will focus on scaling the company’s services to deliver decision-ready toxicology insights earlier in development.

“VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier,” said Tony Lialin, Chief Commercial Officer, VivoSim Labs. “We will scale a high-touch, consultative service from our San Diego lab so pharma and biopharma teams get decision-ready toxicology insights that aim to streamline pre-IND decision-making and reduce late-stage surprises” [2].

Keith Murphy, Executive Chairman of VivoSim Labs, highlighted Lialin’s ability to build solutions that customers need: “Tony has a rare track record of turning disruptive science into durable commercial engines. As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need” [2].

References:

[1] https://www.linkedin.com/posts/partnology_commercial-leadership-genomics-activity-7360752049573031937-xpbm

[2] https://www.globenewswire.com/news-release/2025/08/14/3133448/37000/en/VivoSim-Labs-Appoints-Tony-Lialin-as-Chief-Commercial-Officer.html

[3] https://www.stocktitan.net/news/VIVS/vivo-sim-labs-appoints-tony-lialin-as-chief-commercial-22v552zjb2qi.html